Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of PEX168 in Type 2 Diabetes
NCT01965509Phase 2Completed
- Sponsor
- Hengrui
- Start
- May 2012
- Primary completion
- Aug 2013
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of polyethylene glycol loxenatide in type 2 diabetes mellitus (T2DM), sponsored by Hengrui. Started May 2012; status: completed.
02
Drugs
polyethylene glycol loxenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01965509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01965509.